Cervical cancer is the third most common cancer among women globally and is greatly affecting young females in Africa. In Ghana, it is the second most common cancer among our women. Nearly all cases of cervical cancer can be attributable to persistent infection with Human Papillomavirus (HPV), an extremely common virus of the reproductive tract. Fortunately, pre-cancerous lesions detected early can be treated via a non-invasive procedure that takes less than one minute.
In line with our vision of "An Africa In Good Health", mPharma is launching the "10,000 Women Initiative" which aims to test 10,000 women for HPV, increase awareness and public health education on cervical cancer (and the link between cervical cancer and HPV), treat pre-cancerous lesions and vaccinate eligible women across Ghana and Nigeria over the next six months.
This project will offer:
- Free HPV testing and subsidised testing kits to women in Ghana and Nigeria
- Subsidised treatment to females who test positive for HPV
- Subsidised vaccination to females who test negative for HPV